Copyright
©The Author(s) 2022.
World J Gastrointest Surg. Nov 27, 2022; 14(11): 1260-1271
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1260
Published online Nov 27, 2022. doi: 10.4240/wjgs.v14.i11.1260
Table 6 Changes in platelet counts in group A (7 d of treatment)
| Baseline | Day 2 | Day 5 | Post-treatment | Change | |
| n | 31 | 10 | 26 | 31 | 31 |
| mean ± SD (× 109/L) | 41.87 ± 17.40 | 42.90 ± 29.41 | 42.04 ± 27.39 | 67.74 ± 62.81 | 25.87 ± 57.67 |
| Median (× 109/L) | 45.00 | 41.50 | 42.00 | 54.00 | 10.00 |
| IQR (× 109/L) | 33.00-55.00 | 17.25-54.00 | 19.75-54.25 | 28.00-80.00 | -7.00-44.00 |
| Min, max (× 109/L) | 6.00, 73.00 | 15.00,111.00 | 9.00, 127.00 | 7.00, 303.00 | -34.00, 244.00 |
- Citation: Ding JN, Feng TT, Sun W, Cai XY, Zhang Y, Zhao WF. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study. World J Gastrointest Surg 2022; 14(11): 1260-1271
- URL: https://www.wjgnet.com/1948-9366/full/v14/i11/1260.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v14.i11.1260